New Class of Therapy for Chronic Heart Failure

Graphic- New Class of Therapy for Chronic Heart Failure
Schematic illustration of microdomain organization of the structural protein BIN-1 within t-tubules of the adult ventricular cardiomyocytes. Originally published in Physiol Rev. 2017 January;97(1):227.


In the US, heart failure affects approximately eight million people, carries a poor prognosis, and represents the single largest healthcare cost for people over 65 years old. Most heart failure therapies rely on blocking the deleterious effects of stress hormones on the heart, but therapies aimed at repairing failing heart muscles are lacking. The lab directed by Nora Eccles Harrison Presidential Endowed Chair Robin Shaw, MD, PhD, and Nora Eccles Harrison Cardiovascular Research & Training Institute (CVRTI) investigators, have identified an architectural protein (cBIN1) of heart muscle cells that organizes the intracellular signalizing network responsible for heart muscle contraction and relaxation. They found that lowering cBIN1 caused heart failure progression, and that, in animal models, replacement of cBIN1 by gene therapy rescued failing heart muscle and prevented death. Furthermore, they devised a cBIN1 blood test that can predict hospitalization and death caused by heart failure in patients. Shaw and his team are now preparing for preclinical development of a cBIN1-directed therapy for heart failure. Successful development of such a therapy will significantly improve the lives of Americans and economics of our health care system. 

References:

Issues Icon

BIN1 localizes the L-type calcium channel to cardiac T-tubules. Hong, T.T., et al., PLoS Biol. 2010 February 16; 8(2):e1000312.

Issues Icon

cBIN1 score (cs) identifies ambulatory HFrEF patients and predicts cardiovascular events. Hitzeman, T.C., et al., Front Physiol. 2020 May 25;11:503.

U of U Health Key Faculty Collaborators

TingTing Hong, MD, PhD